JP2022022264A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022022264A5 JP2022022264A5 JP2021189815A JP2021189815A JP2022022264A5 JP 2022022264 A5 JP2022022264 A5 JP 2022022264A5 JP 2021189815 A JP2021189815 A JP 2021189815A JP 2021189815 A JP2021189815 A JP 2021189815A JP 2022022264 A5 JP2022022264 A5 JP 2022022264A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- posaconazole
- patient
- composition according
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 55
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 claims 34
- 229960001589 posaconazole Drugs 0.000 claims 34
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 claims 14
- 229960000572 olaparib Drugs 0.000 claims 14
- 238000000034 method Methods 0.000 claims 8
- 206010033128 Ovarian cancer Diseases 0.000 claims 4
- PURKAOJPTOLRMP-UHFFFAOYSA-N ivacaftor Chemical compound C1=C(O)C(C(C)(C)C)=CC(C(C)(C)C)=C1NC(=O)C1=CNC2=CC=CC=C2C1=O PURKAOJPTOLRMP-UHFFFAOYSA-N 0.000 claims 3
- 229960004508 ivacaftor Drugs 0.000 claims 3
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 2
- 210000000577 adipose tissue Anatomy 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 210000004602 germ cell Anatomy 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 230000000306 recurrent effect Effects 0.000 claims 2
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 1
- 201000001342 Fallopian tube cancer Diseases 0.000 claims 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000026149 Primary peritoneal carcinoma Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 238000011518 platinum-based chemotherapy Methods 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023150724A JP7698009B2 (ja) | 2017-05-16 | 2023-09-19 | Ｃｙｐ３ａ４基質薬物による処置方法 |
| JP2025098467A JP2025137510A (ja) | 2017-05-16 | 2025-06-12 | Ｃｙｐ３ａ４基質薬物による処置方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/596,585 US10376507B2 (en) | 2017-05-16 | 2017-05-16 | Method of treating a patient with a CYP3A4 substrate drug |
| US16/036,678 | 2018-07-16 | ||
| US16/036,678 US20180333411A1 (en) | 2017-05-16 | 2018-07-16 | Methods of treatment |
| PCT/US2018/061141 WO2020018136A1 (en) | 2017-05-16 | 2018-11-14 | Methods of treatment with cyp3a4 substrate drugs |
| JP2020536002A JP6984024B2 (ja) | 2017-05-16 | 2018-11-14 | Ｃｙｐ３ａ４基質薬物による処置方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020536002A Division JP6984024B2 (ja) | 2017-05-16 | 2018-11-14 | Ｃｙｐ３ａ４基質薬物による処置方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023150724A Division JP7698009B2 (ja) | 2017-05-16 | 2023-09-19 | Ｃｙｐ３ａ４基質薬物による処置方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022022264A JP2022022264A (ja) | 2022-02-03 |
| JP2022022264A5 true JP2022022264A5 (enExample) | 2022-03-17 |
| JP7353343B2 JP7353343B2 (ja) | 2023-09-29 |
Family
ID=64269934
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572833A Pending JP2020520380A (ja) | 2017-05-16 | 2017-05-16 | 処置法 |
| JP2020536002A Active JP6984024B2 (ja) | 2017-05-16 | 2018-11-14 | Ｃｙｐ３ａ４基質薬物による処置方法 |
| JP2021008114A Pending JP2021059610A (ja) | 2017-05-16 | 2021-01-21 | 処置法 |
| JP2021189815A Active JP7353343B2 (ja) | 2017-05-16 | 2021-11-24 | Ｃｙｐ３ａ４基質薬物による処置方法 |
| JP2022198263A Pending JP2023021260A (ja) | 2017-05-16 | 2022-12-12 | 処置法 |
| JP2023150724A Active JP7698009B2 (ja) | 2017-05-16 | 2023-09-19 | Ｃｙｐ３ａ４基質薬物による処置方法 |
| JP2025098467A Pending JP2025137510A (ja) | 2017-05-16 | 2025-06-12 | Ｃｙｐ３ａ４基質薬物による処置方法 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572833A Pending JP2020520380A (ja) | 2017-05-16 | 2017-05-16 | 処置法 |
| JP2020536002A Active JP6984024B2 (ja) | 2017-05-16 | 2018-11-14 | Ｃｙｐ３ａ４基質薬物による処置方法 |
| JP2021008114A Pending JP2021059610A (ja) | 2017-05-16 | 2021-01-21 | 処置法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022198263A Pending JP2023021260A (ja) | 2017-05-16 | 2022-12-12 | 処置法 |
| JP2023150724A Active JP7698009B2 (ja) | 2017-05-16 | 2023-09-19 | Ｃｙｐ３ａ４基質薬物による処置方法 |
| JP2025098467A Pending JP2025137510A (ja) | 2017-05-16 | 2025-06-12 | Ｃｙｐ３ａ４基質薬物による処置方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (6) | US10376507B2 (enExample) |
| EP (4) | EP4082546A1 (enExample) |
| JP (7) | JP2020520380A (enExample) |
| KR (3) | KR20210010663A (enExample) |
| AU (10) | AU2017414697B2 (enExample) |
| CA (2) | CA3062770A1 (enExample) |
| DK (2) | DK3426250T3 (enExample) |
| ES (2) | ES2912373T3 (enExample) |
| FI (1) | FI3716976T3 (enExample) |
| HR (1) | HRP20220536T1 (enExample) |
| MX (4) | MX2019013714A (enExample) |
| PL (1) | PL3426250T3 (enExample) |
| SI (1) | SI3426250T1 (enExample) |
| WO (2) | WO2018212764A1 (enExample) |
| ZA (1) | ZA202006746B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3009169A1 (en) | 2015-12-23 | 2017-06-29 | Neurocrine Biosciences, Inc. | Synthetic methods for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) |
| JP7090151B2 (ja) * | 2017-01-27 | 2022-06-23 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| EP4082546A1 (en) | 2017-05-16 | 2022-11-02 | Bow River LLC | Methods of treatment with cyp3a4 substrate drugs |
| US20220143011A1 (en) | 2017-05-16 | 2022-05-12 | Bow River LLC | Methods of treatment with cyp3a4 substrate drugs |
| US10857144B2 (en) | 2017-05-16 | 2020-12-08 | Bow River LLC | Methods of treatment |
| WO2018226875A2 (en) * | 2017-06-07 | 2018-12-13 | University Of Kansas | Methods and medicaments for the treatment of renal cell carcinoma |
| MA50175B1 (fr) | 2017-09-21 | 2025-05-30 | Neurocrine Biosciences, Inc. | Formulation de valbenazine à dosage élevé et compositions, procédés et kits associés |
| KR20250070134A (ko) | 2017-10-10 | 2025-05-20 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| CN109966298A (zh) * | 2019-05-10 | 2019-07-05 | 辽宁大学 | 托伐普坦在制备降血脂药物中的应用 |
| EP3980072A4 (en) * | 2019-06-05 | 2023-06-14 | University of Georgia Research Foundation | COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING HUMAN IMMUNODEFICIENCY VIRUS-ASSOCIATED PULMONARY HYPERTENSION |
| US10940141B1 (en) | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
| EP4041922A4 (en) | 2019-10-07 | 2023-11-01 | University Hospitals Cleveland Medical Center | METHOD FOR TREATING WILD-TYPE ISOCITRATE DEHYDROGENASE-1 CANCER |
| JP7385300B2 (ja) * | 2019-11-15 | 2023-11-22 | 株式会社カルディオインテリジェンス | 医薬品の用法及び用量の少なくとも一方の決定を支援するための方法、プログラム、装置及びシステム |
| EP4073102A4 (en) | 2019-12-12 | 2024-05-08 | Ting Therapeutics LLC | Compositions and methods for the prevention and treatment of hearing loss |
| KR20220161402A (ko) * | 2020-04-01 | 2022-12-06 | 오츠카 세이야쿠 가부시키가이샤 | 아리피프라졸 치료의 용량 개시 방법 |
| WO2022019920A1 (en) * | 2020-07-24 | 2022-01-27 | Verastem, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
| KR102601028B1 (ko) | 2020-08-18 | 2023-11-10 | 재단법인대구경북과학기술원 | 아베마시클립을 유효성분으로 포함하는 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물 |
| WO2022039421A1 (ko) * | 2020-08-18 | 2022-02-24 | 재단법인대구경북과학기술원 | 아베마시클립을 유효성분으로 포함하는 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물 |
| CN111920814B (zh) * | 2020-09-04 | 2022-02-11 | 郑州大学 | 依匹哌唑在制备抗肿瘤药物中的应用 |
| CN112898131B (zh) * | 2020-11-05 | 2023-08-22 | 苏州凯祥生物科技有限公司 | 大麻二酚的提取工艺及大麻二酚或大麻提取物在制备预防或者治疗bph的药物中的应用 |
| CN112206297B (zh) * | 2020-11-16 | 2022-01-11 | 深圳市宝安区人民医院 | 治疗心脾两虚型失眠症的中药制剂及其制备方法 |
| US11229644B1 (en) | 2020-12-31 | 2022-01-25 | Lake O'hara Llc | Methods of treating psychiatric disorders in obese patients with brexpiprazole |
| JP2024502431A (ja) * | 2020-12-31 | 2024-01-19 | レイク オハラ エルエルシー | 肥満患者における、ブレクスピプラゾールを用いた精神疾患の治療方法 |
| CN112675175B (zh) * | 2021-02-01 | 2022-11-01 | 天津济坤医药科技有限公司 | 布里格替尼在制备治疗特发性肺纤维化的药物中的应用 |
| KR102843222B1 (ko) * | 2021-11-30 | 2025-08-06 | 에스케이케미칼 주식회사 | 마이크로조말 트리글리세라이드 전달 단백질 억제제의 섬유화 질환 치료 용도 |
| WO2023141634A2 (en) * | 2022-01-24 | 2023-07-27 | Lake O'hara Llc | Methods of treating psychiatric disorders in obese patients with brexpiprazole |
| WO2023220224A1 (en) * | 2022-05-12 | 2023-11-16 | St. Jude Children's Research Hospital, Inc. | Synergistic antifungal composition and method |
| CN117045643A (zh) * | 2023-09-26 | 2023-11-14 | 江苏百奥信康医药科技有限公司 | 一种cftr矫正剂在制备治疗乳腺增生症的药物中的应用 |
| CN117257994B (zh) * | 2023-11-21 | 2024-03-01 | 北京大学人民医院 | 动物模型的构建方法及应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7973970B2 (en) * | 2000-08-09 | 2011-07-05 | Ether Visuals Llc | Preventing artifacts that may be produced when bottling PDL files converted from raster images |
| EP2023923A2 (en) * | 2006-05-25 | 2009-02-18 | Bristol-Myers Squibb Company | Use of ixabepilone in combination with cyp3a4 inhibitors for pharmaceuticals |
| US7820681B1 (en) * | 2009-01-14 | 2010-10-26 | Mutual Pharmaceutical Company, Inc. | Methods for concomitant administration of colchicine and a second active agent |
| US7816383B1 (en) * | 2009-12-04 | 2010-10-19 | Intermune, Inc. | Methods of administering pirfenidone therapy |
| US20140221424A1 (en) * | 2013-01-30 | 2014-08-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for use in the treatment of cystic fibrosis |
| LT3223796T (lt) | 2014-11-25 | 2021-10-25 | Curadigm Sas | Farmacinės kompozicijos, jų gamyba ir panaudojimo būdai |
| US10493024B2 (en) | 2015-10-12 | 2019-12-03 | Hk Tumescent Pharma Corporation | Tumescent infiltration drug delivery of high subcutaneous drug concentrations with prolonged local and systemic effects and minimal local or systemic toxicity |
| WO2017165635A1 (en) | 2016-03-25 | 2017-09-28 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome p450 modulators |
| EP3538106A4 (en) | 2016-11-09 | 2021-03-24 | Signpath Pharma, Inc. | PROTECTIVE EFFECT OF DMPC, DMPG, DMPC / DMPG, LYSOPG AND LYSOPC AGAINST MEDICINAL PRODUCTS THAT CAUSE CANALOPATHIA |
| US10857144B2 (en) | 2017-05-16 | 2020-12-08 | Bow River LLC | Methods of treatment |
| EP4082546A1 (en) | 2017-05-16 | 2022-11-02 | Bow River LLC | Methods of treatment with cyp3a4 substrate drugs |
-
2017
- 2017-05-16 EP EP22163202.9A patent/EP4082546A1/en active Pending
- 2017-05-16 DK DK17897227.9T patent/DK3426250T3/da active
- 2017-05-16 US US15/596,585 patent/US10376507B2/en active Active
- 2017-05-16 MX MX2019013714A patent/MX2019013714A/es unknown
- 2017-05-16 ES ES17897227T patent/ES2912373T3/es active Active
- 2017-05-16 PL PL17897227.9T patent/PL3426250T3/pl unknown
- 2017-05-16 CA CA3062770A patent/CA3062770A1/en active Pending
- 2017-05-16 KR KR1020217001925A patent/KR20210010663A/ko not_active Ceased
- 2017-05-16 HR HRP20220536TT patent/HRP20220536T1/hr unknown
- 2017-05-16 SI SI201731136T patent/SI3426250T1/sl unknown
- 2017-05-16 KR KR1020197036786A patent/KR20200010320A/ko not_active Ceased
- 2017-05-16 WO PCT/US2017/032924 patent/WO2018212764A1/en not_active Ceased
- 2017-05-16 AU AU2017414697A patent/AU2017414697B2/en active Active
- 2017-05-16 JP JP2019572833A patent/JP2020520380A/ja active Pending
- 2017-05-16 EP EP17897227.9A patent/EP3426250B1/en active Active
- 2017-08-07 US US15/670,271 patent/US20180333410A1/en not_active Abandoned
-
2018
- 2018-07-16 US US16/036,678 patent/US20180333411A1/en not_active Abandoned
- 2018-11-14 WO PCT/US2018/061141 patent/WO2020018136A1/en not_active Ceased
- 2018-11-14 CA CA3103793A patent/CA3103793A1/en active Pending
- 2018-11-14 KR KR1020217004371A patent/KR102805232B1/ko active Active
- 2018-11-14 JP JP2020536002A patent/JP6984024B2/ja active Active
- 2018-11-14 US US16/191,351 patent/US10835529B2/en active Active
- 2018-11-14 EP EP18926463.3A patent/EP3716976B1/en active Active
- 2018-11-14 EP EP24193158.3A patent/EP4461298A3/en active Pending
- 2018-11-14 DK DK18926463.3T patent/DK3716976T3/da active
- 2018-11-14 AU AU2018432858A patent/AU2018432858B2/en active Active
- 2018-11-14 ES ES18926463T patent/ES2993832T3/es active Active
- 2018-11-14 FI FIEP18926463.3T patent/FI3716976T3/fi active
- 2018-11-14 MX MX2021000609A patent/MX2021000609A/es unknown
-
2019
- 2019-03-12 US US16/351,198 patent/US20190255043A1/en not_active Abandoned
- 2019-11-15 MX MX2022013410A patent/MX2022013410A/es unknown
-
2020
- 2020-03-24 AU AU2020202100A patent/AU2020202100B2/en active Active
- 2020-03-30 AU AU2020202266A patent/AU2020202266B2/en active Active
- 2020-06-02 AU AU2020203606A patent/AU2020203606B2/en active Active
- 2020-06-02 AU AU2020203608A patent/AU2020203608B2/en active Active
- 2020-06-02 AU AU2020203607A patent/AU2020203607B2/en active Active
- 2020-10-08 AU AU2020250281A patent/AU2020250281B2/en active Active
- 2020-10-29 ZA ZA2020/06746A patent/ZA202006746B/en unknown
- 2020-11-16 US US17/099,298 patent/US11123346B2/en active Active
-
2021
- 2021-01-15 MX MX2025000380A patent/MX2025000380A/es unknown
- 2021-01-21 JP JP2021008114A patent/JP2021059610A/ja active Pending
- 2021-11-24 JP JP2021189815A patent/JP7353343B2/ja active Active
-
2022
- 2022-07-05 AU AU2022204806A patent/AU2022204806B2/en active Active
- 2022-09-08 AU AU2022228153A patent/AU2022228153B2/en not_active Expired - Fee Related
- 2022-12-12 JP JP2022198263A patent/JP2023021260A/ja active Pending
-
2023
- 2023-09-19 JP JP2023150724A patent/JP7698009B2/ja active Active
-
2025
- 2025-06-12 JP JP2025098467A patent/JP2025137510A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022022264A5 (enExample) | ||
| JP2023174661A5 (enExample) | ||
| JP2022009090A5 (enExample) | ||
| JP2022031478A5 (enExample) | ||
| JP2009539769A5 (enExample) | ||
| JP2017516802A5 (enExample) | ||
| JP2020523356A5 (enExample) | ||
| JP2021169534A5 (enExample) | ||
| JP2008526927A5 (enExample) | ||
| JP2012525358A5 (enExample) | ||
| WO2017148129A1 (zh) | 一种用于治疗恶病质的药物组合物及其应用 | |
| JPWO2021045159A5 (enExample) | ||
| JP2019513706A5 (enExample) | ||
| CN113893256A (zh) | 化合物或其可药用盐、二聚体或三聚体在制备治疗癌症的药物中的应用 | |
| CN104936585B (zh) | 包括苯肾上腺素和扑热息痛的组合药剂 | |
| CN110638802A (zh) | Atca在制备治疗肿瘤的药物中的用途 | |
| CN106038566B (zh) | 一种用于胃癌治疗的药物组合物及其应用 | |
| CN105769849B (zh) | 一种治疗卵巢癌的药物组合物 | |
| WO2003045406A1 (en) | An chinese medicinal formulation treating stomachache, rib-side pain, headache and menstrual pain | |
| JPWO2020112765A5 (enExample) | ||
| CN107375491A (zh) | 一种用于治疗子宫内膜异位症的温经异痛舒中药复方及其制备方法 | |
| CN106943392B (zh) | 一种用于治疗小儿疝气的药物组合物及其用途 | |
| Bertolín | Pipeline on the Move | |
| CN104840829B (zh) | 缓解红霉素和阿奇霉素不良反应的外敷中药及其使用方法 | |
| JPWO2021214253A5 (enExample) |